Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00991029 · ClinicalTrials.gov registry record · Phase 3
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
A Phase 3 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4,881
- Enrollment target
NCT00991029: Clinical Trial Phase 3 study, sponsored by University of California, San Francisco.
NCT00991029 is a Phase 3 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 4,881 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (532% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00991029, a Phase 3 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4,881 participants
- Enrollment target
Study Summary
A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an NIH Stroke Scale \[NIHSS\] score less than or equal to 3). TIAs are common \[25\], and are often harbingers of disabling strokes. Approximately 250,000-350,000 TIAs are diagnosed each year in the US. Given median survival of more than 8 years \[32\], there are approximately 2.4 million TIA survivors. In a national survey, one in fifteen of those over 65 years old reported a history of TIA \[33\], which is equivalent to a prevalence of 2.3 million in older Americans. Based on the prevalence of undiagnosed transient neurological events, the true incidence of TIA may be twice as high as the rates of diagnosis \[33\]. Based on our review of the National Inpatient Sample for 1997-2003, there were an average of 200,000 hospital admissions for TIA each year, with annual charges climbing quickly in the period to $2.6 billion in 2003. Composite endpoint of new ischemic vascular events: ischemic stroke, myocardial infarction or ischemic vascular death at 90 days.
Primary Outcome
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes
Interventions
- DRUG placebo
- DRUG Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,881 participants |
| Start Date | 2010-05-28 |
| Est. Completion | 2018-04-09 |
| Phase | Phase 3 |
Why NCT00991029 stopped before completion
NCT00991029 is an interventional study that assigns participants to a tested intervention. Its 4,881 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (532% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00991029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00991029 about?
NCT00991029 is a clinical study titled "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial". A transient ischemic attack (TIA) is a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. An ischemic stroke is a cerebral infarction. In POINT, eligibility is limited to brain TIAs and to minor ischemic strokes (with an N...
What is the current status of trial NCT00991029?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4,881 participants. The study started on 2010-05-28. Estimated completion is 2018-04-09.
What interventions are being tested in trial NCT00991029?
The interventions under investigation include: placebo (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT00991029?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00991029's enrollment target sits among peer trials
4,881 52nd of 2000 higher than 1,949 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
- NCT05929976 · 4,900 participants
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI